Intra-Arterial Thrombolysis After SUCCESSful Angiographic Recanalization in Acute Large Vessel Occlusion Stroke of the Anterior Circulation: the IA-SUCCESS Multicenter, Randomized Clinical Trial

Stroke is a leading cause of disability and mortality worldwide. Despite the clinical benefit of mechanical thrombectomy, 1 out of 2 patients treated are functionally independent at 90 days. Achieving the best possible angiographic reperfusion is a key determinant of clinical outcome in acute ischemic stroke patients with anterior circulation large vessel occlusion. Mechanical thrombectomy is standard treatment for large vessel occlusion stroke patients within 24. In the setting of successful (eTICI ≥2b), adjunct intra-arterial thrombolysis may be a promising therapeutic option allowing recanalization of distal arterial occlusions (not accessible to mechanical devices) and improvement of upstream brain reperfusion by targeting microvascular obstruction.
The IA-SUCCESS randomized trial aims to assess the clinical and safety of adjunct intra-arterial thrombolysis vs. no adjunct intra-arterial thrombolysis after successful angiographic reperfusion in patients with acute anterior circulation large vessel occlusion stroke.

Start Date01 Jun 2025

Sponsor / Collaborator-

ChiCTR2500099976

/ SuspendedNot ApplicableIIT

A multicenter randomized controlled clinical study comparing the safety and efficacy of vitrectomy combined with subretinal injection of alteplase and intravitreal injection of alteplase combined with pneumatic displacement in the treatment of massive macular subretinal hemorrhage caused by age-related macular degeneration

Start Date10 Apr 2025

Sponsor / Collaborator

The Second Affiliated Hospital of Xi'an Jiaotong University

NCT07003646

/ RecruitingNot Applicable

Reperfusion Treatment in Acute Pulmonary Embolism: A Multicenter Observational Study in the Nordic Countries

International guidelines recommend immediate reperfusion with systemic thrombolysis (ST) as first-line treatment in high-risk pulmonary embolism (PE). The therapy improves hemodynamics and overall survival but is also associated with a significant risk of severe bleeding. Catheter-directed intervention (CDI) is recommended as an alternative reperfusion therapy in high-risk PE when ST is contraindicated or has failed, as well as in patients who deteriorate or fail to improve during anticoagulation (AC) treatment. Despite lack of high-quality evidence and randomized studies between CDI and standard care, the use of CDI is spreading rapidly in high-risk PE and in less severe PE not fulfilling current treatment criteria.

Start Date01 Apr 2025

Sponsor / Collaborator

Sahlgrenska Universitetssjukhuset

[+8]

100 Clinical Results associated with Alteplase

100 Translational Medicine associated with Alteplase

100 Patents (Medical) associated with Alteplase

13,836

Literatures (Medical) associated with Alteplase

01 Apr 2026·Neural Regeneration Research

Recombinant tissue plasminogen activator protects neurons after intracerebral hemorrhage through activating the PI3K/AKT/mTOR pathway

Article

Author: Zhang, Ping ; Wu, Xuan ; Wang, Jingyi ; Chen, Shiling ; Liu, Xia ; Wang, Jiahui ; Tang, Zhouping ; Yang, Jingfei ; Jing, Jie ; Li, Yunjie

JOURNAL/nrgr/04.03/01300535-202604000-00038/figure1/v/2025-06-30T060627Z/r/image-tiff Recombinant tissue plasminogen activator is commonly used for hematoma evacuation in minimally invasive surgery following intracerebral hemorrhage. However, during minimally invasive surgery, recombinant tissue plasminogen activator may come into contact with brain tissue. Therefore, a thorough assessment of its safety is required. In this study, we established a mouse model of intracerebral hemorrhage induced by type VII collagenase. We observed that the administration of recombinant tissue plasminogen activator without hematoma aspiration significantly improved the neurological function of mice with intracerebral hemorrhage, reduced pathological damage, and lowered the levels of apoptosis and autophagy in the tissue surrounding the hematoma. In an in vitro model of intracerebral hemorrhage using primary cortical neurons induced by hemin, the administration of recombinant tissue plasminogen activator suppressed neuronal apoptosis, autophagy, and endoplasmic reticulum stress. Transcriptome sequencing analysis revealed that recombinant tissue plasminogen activator upregulated the phosphoinositide 3-kinase/RAC-alpha serine/threonine-protein kinase/mammalian target of rapamycin pathway in neurons. Moreover, the phosphoinositide 3-kinase inhibitor LY294002 abrogated the neuroprotective effects of recombinant tissue plasminogen activator in inhibiting excessive apoptosis, autophagy, and endoplasmic reticulum stress. Furthermore, to specify the domain of recombinant tissue plasminogen activator responsible for its neuroprotective effects, various inhibitors were used to target distinct domains. It has been revealed that the epidermal growth factor receptor inhibitor AG-1478 reversed the effect of recombinant tissue plasminogen activator on the phosphoinositide 3-kinase/RAC-alpha serine/threonine-protein kinase/mammalian target of rapamycin pathway. These findings suggest that recombinant tissue plasminogen activator exerts a direct neuroprotective effect on neurons following intracerebral hemorrhage, possibly through activation of the phosphoinositide 3-kinase/RAC-alpha serine/threonine-protein kinase/mammalian target of rapamycin pathway.

01 Jan 2026·Neural Regeneration Research

Neuroserpin alleviates cerebral ischemia-reperfusion injury by suppressing ischemia-induced endoplasmic reticulum stress

Article

Author: Molnár, Zoltán ; Shi, Qiaoyun ; Zhang, Qinghua ; Peng, Yinghui ; Zhang, Xiao-Qi ; Zhong, Peiyun ; Huang, Zijian ; Liu, Wei ; Shi, Lei ; Adorján, István ; Liao, Yumei ; Liu, Peng ; Fukuzaki, Yumi ; Ma, Nan ; Zhang, Shiqing ; Guo, Lingling ; Zhang, Xiaoshen ; Kawashita, Eri

JOURNAL/nrgr/04.03/01300535-202601000-00037/figure1/v/2025-03-30T110608Z/r/image-tiff Neuroserpin, a secreted protein that belongs to the serpin superfamily of serine protease inhibitors, is highly expressed in the central nervous system and plays multiple roles in brain development and pathology. As a natural inhibitor of recombinant tissue plasminogen activator, neuroserpin inhibits the increased activity of tissue plasminogen activator in ischemic conditions and extends the therapeutic windows of tissue plasminogen activator for brain ischemia. However, the neuroprotective mechanism of neuroserpin against ischemic stroke remains unclear. In this study, we used a mouse model of middle cerebral artery occlusion and oxygen-glucose deprivation/reperfusion-injured cortical neurons as in vivo and in vitro ischemia-reperfusion models, respectively. The models were used to investigate the neuroprotective effects of neuroserpin. Our findings revealed that endoplasmic reticulum stress was promptly triggered following ischemia, initially manifesting as the acute activation of endoplasmic reticulum stress transmembrane sensors and the suppression of protein synthesis, which was followed by a later apoptotic response. Notably, ischemic stroke markedly downregulated the expression of neuroserpin in cortical neurons. Exogenous neuroserpin reversed the activation of multiple endoplasmic reticulum stress signaling molecules, the reduction in protein synthesis, and the upregulation of apoptotic transcription factors. This led to a reduction in neuronal death induced by oxygen/glucose deprivation and reperfusion, as well as decreased cerebral infarction and neurological dysfunction in mice with middle cerebral artery occlusion. However, the neuroprotective effects of neuroserpin were markedly inhibited by endoplasmic reticulum stress activators thapsigargin and tunicamycin. Our findings demonstrate that neuroserpin exerts neuroprotective effects on ischemic stroke by suppressing endoplasmic reticulum stress.

31 Dec 2025·Hospital practice (1995)

Modified infusion of recombinant tissue plasminogen activator in high-risk pulmonary thromboembolism with high bleeding risk: a case report

Article

Author: Shahri, Bahram ; Ahmadi, Mostafa ; Baradaran Rahimi, Vafa ; Yadollahi, Asal ; Hasin, Mohammad Hussein

High-risk pulmonary thromboembolism (PTE) is a form of venous thromboembolism that refers to severe obstruction of pulmonary vessels, which causes right ventricular failure and hemodynamic instability. High-risk PTE has a high mortality rate unless immediate reperfusion treatment is done. Systemic thrombolysis is recommended for patients with high-risk PTE. The approved regimen for high-risk PTE is the accelerated intravenous administration of recombinant tissue-type plasminogen activator (rtPA) 100 mg over 2 hours. Herein, we present a case of high-risk PTE in a 74-year-old woman with a high risk of bleeding due to a recent pelvic fracture and head trauma who was successfully treated with a slower infusion of 100 mg rtPA over 4 hours. The modified infusion rate of 100 mg rtPA over 4 hours is an effective regimen for thrombolysis in acute high-risk PTE. It might have a lower risk of bleeding complications, which makes it a good option for patients with high bleeding risk.

News (Medical) associated with Alteplase

08 Jul 2025

·www.einpresswire.com

Study Demonstrates Low Intensity Focused Ultrasound Effectively Breaks Down Microclots Linked to Long COVID-19 Symptoms

Openwater’s device could offer a promising, affordable, and drug-free solution for long COVID therapies Our study demonstrates that low-intensity focused ultrasound can safely and effectively break down these persistent clots, without the need for surgery or clot-dissolving drugs.” — Aaron Timm, CEO of Openwater SAN FRANCISCO, CA, UNITED STATES, July 8, 2025 / EINPresswire.com / -- Openwater, an open-source medical technology company delivering portable, hospital-grade diagnostic and therapeutic devices, today announced new research showing that low-intensity focused ultrasound (LIFU) can effectively break down amyloid fibrinogen microclots associated with long COVID symptoms. Published in the Journal of Frontiers in Bioengineering and Biotechnology, the in vitro study demonstrates low-frequency ultrasound at 150 kHz is the most effective frequency for reducing both microclot count and size. Approximately 60% of U.S. adults have had COVID, and of those, 30% report lingering long COVID symptoms, including fatigue, pain, breathlessness, headaches, and cognitive difficulties. Amyloid fibrinogen microclots, tiny protein aggregates that can disrupt perfusion and cause inflammation, are linked to these symptoms. Current therapies, including clot-dissolving drugs, like recombinant tissue plasminogen activators (rtPA), and invasive blood filtration, often fail to fully resolve microclots and can pose significant risks. In order to improve the lysis, or disintegration, of these clots, researchers theorized microbubble-assisted ultrasound or rtPA-assisted ultrasound may improve the standard of care, and set out to understand the exact effects of ultrasound therapy alone and in combination with these additional measures. In the study, Low-Intensity Ultrasound Lysis of Amyloid Microclots in a Lab-on-Chip Model, researchers created artificial microclots mimicking those found in long COVID patients. Using Openwater’s Open-LIFU technology, they tested how effectively LIFU could break down clots at different frequencies. Microclots were exposed to ultrasound waves at 150 kHz, 300 kHz, 500 kHz, and 1 MHz under four conditions: ultrasound alone, ultrasound with microbubbles, ultrasound with rtPA, and ultrasound with both microbubbles and rtPA. The study found that 150 kHz ultrasound significantly fragmented these hard-to-treat clots, reducing their size and number by up to threefold. Openwater’s study establishes non-invasive LIFU as a safe and effective treatment, capable of breaking down microclots without surgery or pharmaceuticals. Key findings from the study include: - Low-frequency (150 kHz) ultrasound alone can break down microclots up to three times more effectively than higher frequencies, without the need for exogenous microbubbles or additional drugs. - The combination of low intensity ultrasound with microbubbles results in acoustic streaming effects which cause microclot lysis. The use of a thrombolytic agent, recombinant tissue plasminogen activators (rtPA), further increases microclot lysis. “Microclots are increasingly recognized as a key factor in persistent long COVID symptoms that can significantly impact quality of life, such as fatigue, breathlessness, and cognitive dysfunction, yet treatment options remain limited,” said Dr. Soren Konecky, Chief Technology Officer at Openwater. “These results show that our portable LIFU device could provide a safer way to restore blood flow and potentially relieve chronic inflammation.” “Today’s treatments for microclots are often invasive and carry significant risks for patients,” added Aaron Timm, Openwater’s CEO. “Our study demonstrates that low-intensity focused ultrasound can safely and effectively break down these persistent clots, without the need for surgery or clot-dissolving drugs. The results of this study offer hope for a safer, non-invasive solution to help people suffering from long COVID symptoms.” As the healthcare community searches for effective long COVID therapies, Openwater’s platform could offer a promising, affordable, and drug-free solution suitable for clinics, urgent care centers, and even home use. Looking ahead, Openwater is committed to making this technology widely accessible, with a goal to reduce the device’s cost to $500 within the next several years. Ongoing research and development, including AI-driven enhancements, aim to further improve precision, ease-of-use, and patient outcomes. For more information, visit www.openwater.health. About Openwater Openwater is an AI-driven medical technology company founded by Dr. Mary Lou Jepsen to make hospital-grade care universally accessible. Backed by notable supporters including Khosla Ventures, Plum Alley, BOLD Capital Partners, Vitalik Buterin, Esther Dyson, and Peter Gabriel, Openwater employs open-source development and consumer electronics manufacturing to lower the cost and speed the delivery of non-invasive medical devices. The company collaborates with leading institutions worldwide to research, validate, and distribute these technologies, aiming to reach patients across borders and income levels. community@openwater.health Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical Result

17 Jun 2025

·www.einpresswire.com

Aspiration Catheter Recall: Q’Apel Medical, Inc. Removes Hippo 072 Aspiration System and Cheetah Delivery Tool After FDA Warning Letter About Internal Processes and Distal Tip Characteristics

This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Products Product Names: 072 Aspiration System or Hippo 072 Aspiration System including Cheetah Delivery Tool and Aspiration Tubing Product Description Unique Device Identifier Manufacturer’s Product Catalog Number Lot Number Expiration Date (MM/DD/YYYY) 072 Aspiration System with Aspiration Tubing 00857545008127 APT6072-132 FG241008C-03 04/07/2025 FG240916C-04 03/17/2025 FG240905C-04 03/06/2025 072 Aspiration System 00857545008097 AP6072-132 FG241206A-03 06/08/2025 FG240917A-01 03/17/2025 072 Aspiration Tubing 00857545008103 APT-95 FG241206A-04 06/08/2025 What to Do On February 26, 2025, Q’Apel Medical, Inc. sent all affected customers a Voluntary Medical Device Removal and Discontinuation letter recommending the following actions: Quarantine any remaining Hippo 072 Aspiration Systems. Return all remaining systems to Q’Apel Medical, Inc. to receive credit. Do not destroy devices. Let Q’Apel Medical, Inc. know if the product was transferred to others so they can be notified and systems can be retrieved. Complete the customer Acknowledgement and Response Card included with the letter to make sure Q’Apel has accounted for all devices. Once the Acknowledgement and Response Card is completed, Q’Apel Medical, Inc. will provide a Returned Material Authorization (RMA) number and shipping or pick up instructions. Reason for Recall Q’Apel Medical, Inc. is recalling Hippo 072 Aspiration Systems after receiving an FDA warning letter that raised concerns about internal processes and the scope of clearance for the Hippo product, as it relates to the distal tip. Specifically, the FDA has raised questions about the features and characteristics of the distal tip of the aspiration catheter when removing a clot during aspiration. The use of affected product may cause serious adverse health consequences, including contractions (vasospasm) or tears (rupture) in the blood vessels, and death. At this time, Q’Apel Medical, Inc. has reported two injuries related to this issue. There have been no reports of death. Device Use The Hippo 072 Aspiration System is indicated for use to remove blood clots in the brain that are blocking blood flow and causing stroke within 8 hours of symptom onset. Patients who are not able to receive a treatment called tissue plasminogen activator (t-PA) through the blood vessels (intravenously, or by IV) or whose clots did not respond to IV t-PA therapy are candidates for treatment with this device. Contact Information Customers in the U.S. with questions about this recall should contact Q’Apel Medical, Inc. customer service at orders@qapelmedical.com or 510-738-6255. Additional FDA Resources: Additional Company Resources: Unique Device Identifier (UDI) The unique device identifier (UDI) helps identify individual medical devices sold in the United States from distribution to use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified more quickly, and as a result, problems potentially resolved more quickly. How do I report a problem? Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Content current as of: 06/17/2025 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

11 Jun 2025

·www.globenewswire.com

Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral ischemic strokeWILLOWBROOK, Ill., June 11, 2025 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz" or the "Company"), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million equity investment from Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies), one of the world’s leading pharmaceutical companies. This strategic investment brings Sun Pharma’s total commitment in Pharmazz to $40 million (including a previous $15 million equity investment). “We believe sovateltide has the potential to redefine the treatment of ischemic stroke, which has not seen a new FDA approved non-thrombolytic therapy in over 30 years. This investment means we are now fully funded to complete our pivotal Phase 3 study and execute on our mission to make this first in class therapy available to stroke patients,” said Emeritus Prof. Anil Gulati, CEO and Founder of Pharmazz. “We deeply value Sun Pharma’s continued partnership, which strengthens our ability to bring our therapies to patients worldwide.” The new funding will provide Pharmazz with the capital required to complete the pivotal U.S. Phase 3 clinical trial of sovateltide (known as Tycamzzi® and Tyvalzi™ in international markets), its lead drug candidate for treating acute cerebral ischemic stroke. Dr. Neil Marwah, President of Pharmazz, added, “This investment gives us the operational runway to execute a complex, multi-country clinical trial and scale the company responsibly as we prepare for a potential public offering. We are thrilled to strengthen our partnership with Sun Pharma, whose continued support reflects deep confidence in our platform and our ability to execute.” Phase 3 Trial of Sovateltide for Stroke Covered by Special Protocol Assessment Sovateltide is a first-in-class endothelin-B receptor agonist to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptoms. Pharmazz has received agreement from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the study design and statistical analysis plan of its Phase 3 clinical trial of sovateltide for the treatment of acute cerebral ischemic stroke patients. Pharmazz is initiating the Phase 3 RESPECT-ETB (ClinicalTrials.gov ID: NCT05691244) trial at 65 sites in the US, Germany, Spain, and the UK, designed to enroll 514 stroke patients. The primary endpoint is the proportion of patients demonstrating functional independence post-stroke, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after stroke onset. Commercially Approved in India: Early Validation from 60,000+ patients Sovateltide was approved in 2023 in India and marketed by Sun Pharma under the brand name Tyvalzi™, offering compelling proof of concept for global commercialization. In a randomized, placebo-controlled, multicenter clinical trial conducted in 158 cerebral ischemic stroke patients conducted in India, the product was shown to be well tolerated and effective in improving neurological outcomes when administered within 24 hours of stroke symptoms. Patients on Sovateltide were 22.7% more likely to achieve functional independence at 90 days (as measured by mRS score 0–2; p=0.0045)Sovateltide delivered a 17.1% higher rate of favorable National Institutes of Health Stroke Scale (NIHSS) scores (p=0.0024)The ordinal shift in mRS and NIHSS score between control and sovateltide groups was favorable towards sovateltide across the entire range.Results represent the first statistically significant clinical data in stroke in 30 years, since the introduction of alteplase (tPA)Over 60,000 patients treated to date since commercial launch in India Targeting a Multibillion-Dollar Market with a Broader Therapeutic Window Stroke remains one of the leading causes of disability and death globally, with over 7 million ischemic strokes annually. Today, fewer than 15% of patients receive approved interventions, largely due to their narrow treatment window and strict eligibility criteria. Sovateltide’s 24-hour dosing window and broader eligibility could expand access—particularly for underserved populations—and position it as a major advance in acute stroke care. If successful in Phase 3 and subsequently approved, sovateltide has strong commercial potential and is expected to be a foundational product in the Pharmazz emerging neurology franchise. About Sovateltide Sovateltide is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Sovateltide is unique because its action site is the neural progenitor cells. Sovateltide promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. About Pharmazz, Inc. Pharmazz is a privately held company developing novel products in critical care medicine. Pharmazz, Inc. obtained marketing authorization for two of its first-in-class drug molecules, centhaquine and sovateltide, for hypovolemic shock and ischemic stroke, respectively, in India. In addition, the US Food and Drug Administration (FDA) has approved two phase III INDs for centhaquine as an agent for hypovolemic shock and sovateltide for cerebral ischemic stroke. Additional information may be found on the Company's website, www.pharmazz.com. About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050): Sun Pharma is the world’s leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. and global emerging markets. Sun Pharma’s high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com. Disclaimer: Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: Pharmazz, Inc. Investors Kabir MarwahMediaShruti Gulati Tel+1 630 780 6087 Tel+1 630 780 6087E mailkabir.marwah@pharmazz.com E mailshruti.gulati@pharmazz.com

Phase 3Drug Approval

100 Deals associated with Alteplase

External Link

KEGG	Wiki	ATC	Drug Bank
D02837	Alteplase	B01AD02 S01XA13	DB00009

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myocardial Infarction	Japan	Kyowa Kirin Co., Ltd.	29 Mar 1991
Myocardial Infarction	Japan	Mitsubishi Tanabe Pharma Corp.	29 Mar 1991
Stroke	Japan	Kyowa Kirin Co., Ltd.	29 Mar 1991
Stroke	Japan	Mitsubishi Tanabe Pharma Corp.	29 Mar 1991
Acute Ischemic Stroke	United States	Genentech, Inc.	13 Nov 1987
Acute myocardial infarction	United States	Genentech, Inc.	13 Nov 1987
Pulmonary Embolism	United States	Genentech, Inc.	13 Nov 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	Austria	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	Belgium	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	Brazil	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	France	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	Germany	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	India	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	Italy	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	Malaysia	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	Mexico	Boehringer Ingelheim GmbH	16 Dec 2020
COVID-19	Phase 3	Netherlands	Boehringer Ingelheim GmbH	16 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2025	Not Applicable	Tuberculosis, Pleural adenosine deaminase (ADA)	-	Intrapleural Lytics	hxrganbsts(cencchyepm) = wdukcrxexz kcdbhspzys (iahqqdhiwp )	-	16 May 2025
ATS2025	Not Applicable	-	-	Intrapleural Alteplase and Dornase	xtiyxovzzl(ldcfvtkjtc) = sfklwtkgvt fvtivhyzcj (qodrldlkhm ) View more	-	16 May 2025
NCT03889249 (AcT Trial, Pubmed \| Stroke)	Phase 3	-	1,577	Alteplase	ygrjuhubhg(wnvzkohkvq) = dzejonstar itfthrnryb (ixbivbeezf )	Negative	01 May 2025
				Tenecteplase	ygrjuhubhg(wnvzkohkvq) = ldcxgjamli itfthrnryb (ixbivbeezf )
P1-13.013 (AAN2025)	Not Applicable	Acute Ischemic Stroke	279	Alteplase	jgvrunajbx(wgoydxfhxd) = wkcvcmlpdt dceaudkdxk (louzsvifcw, 40 - 69)	Positive	07 Apr 2025
				Tenecteplase	jgvrunajbx(wgoydxfhxd) = pixhmofwuv dceaudkdxk (louzsvifcw, 37 - 65)
S22.010 (AAN2025)	Not Applicable	Stroke	280	Alteplase (TPA)	yyoempajin(qpjgvnnhnw) = jvndmdvfcw kmjytrxctn (kebxlahhyj ) View more	Positive	07 Apr 2025
				Tenecteplase (TNK)	yyoempajin(qpjgvnnhnw) = frnyafelsf kmjytrxctn (kebxlahhyj ) View more
P7-13.013 (AAN2025)	Not Applicable	Stroke	280	Tenecteplase (TNK)	suqcdvcnmn(pzlqlzkouu) = luljlfbcow hanrndouoe (ygurpcptfb ) View more	Positive	07 Apr 2025
				Alteplase (TPA)	suqcdvcnmn(pzlqlzkouu) = iednabkwry hanrndouoe (ygurpcptfb ) View more
NCT05429476 (EXPECTS, Pubmed \| N Engl J Med) Manual	Phase 3	Ischemic Attack, Transient	234	Alteplase	lzmarctafz(grsbaxchkb) = pdnlxdanyd neexdpxtdr (xamqmzwbel ) View more	Positive	03 Apr 2025
				Standard Medical Treatment	lzmarctafz(grsbaxchkb) = jgorfxofof neexdpxtdr (xamqmzwbel ) View more
NEWS Manual	Not Applicable	Stroke	372	Alteplase	isyjmddvsj(pfmwqjwbkl) = caajqplblx tijrkadtuu (uqaripsssy ) View more	Positive	07 Feb 2025
				Standard care (antiplatelet therapy)	isyjmddvsj(pfmwqjwbkl) = pzfdpxgwpa tijrkadtuu (uqaripsssy ) View more
ISC2025	Not Applicable	Acute Ischemic Stroke	1,556	TNK	tmxnpggnzr(ysnmexmcvh) = Median ASPECTS was lower in the sICH group xsvztagotw (omdtpiahkn )	Positive	30 Jan 2025
				tPA
HDSA (ISC2025)	Not Applicable	Stroke	574	Alteplase	ocjbxjwzrc(vswcutvowt): OR = 0.11 (95% CI, 0.01 - 0.84), P-Value = 0.03	Positive	30 Jan 2025
				Tenecteplase

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis